Mathilde B.
- Country
- France
- Department
- Medical oncology
Research Overview
Data & Insights
Has run more than one trial at 0 of 41 partner sites.
Specializations
Targeted and Immunotherapy Strategies in Solid Tumors
Focus on precision agents for non‑small cell lung cancer, breast cancer, and prostate cancer, integrating molecular biomarkers and immune‑checkpoint modulation.
- EGFR exon 20 insertion inhibitors
- KRAS G12C directed therapies
- PARP inhibitors for HRR‑mutated prostate disease
Clinical impact is assessed across metastatic, locally advanced, and high‑risk early disease settings.
Advances in Hematologic Oncology
Investigation of novel agents in multiple myeloma, lymphoma, and myelodysplastic syndromes, emphasizing disease‑modifying outcomes.
- Antibody‑drug conjugates in mantle cell lymphoma
- Combination regimens for relapsed/refractory myeloma
- Targeted therapies for HRR‑mutated myelodysplastic disease
Therapeutic efficacy is measured through progression‑free survival and minimal residual disease metrics.
Autoimmune Vasculitis and Systemic Diseases
Clinical evaluation of immunosuppressive strategies in ANCA‑associated vasculitis, systemic sclerosis, and multiple sclerosis.
- Rituximab versus ocrelizumab comparative outcomes
- Prednisone tapering protocols in vasculitis remission maintenance
- Extended therapy cessation in secondary progressive multiple sclerosis
Endpoints include disease‑free survival and relapse‑free intervals.
Respiratory and Renal Comorbidity Management
Therapeutic research addressing chronic obstructive pulmonary disease, moderate‑to‑severe asthma, chronic kidney disease, and associated hypertension.
- Novel inhaled agents for uncontrolled asthma
- Renal protective strategies combined with antihypertensive therapy
- Impact of COPD management on oncology treatment tolerance
Outcomes focus on lung function preservation and renal function trajectory.
Infectious Complications in Oncology Patients
Study of antimicrobial approaches for staphylococcal prosthetic joint infection, catheter‑related bloodstream infection, and staphylococcal endocarditis in immunocompromised cohorts.
- Single‑dose dalbavancin versus standard antibiotic courses
- Debridement‑antibiotics‑implant retention (DAIR) efficacy
- Risk stratification for infection recurrence post‑oncologic therapy
Safety and infection‑free survival are primary evaluation criteria.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.